ReviewBone marrow transplantation2015
Improving the clinical outcome of unmanipulated haploidentical blood and marrow transplantation.
Review in Bone marrow transplantation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 15 citations in OpenAlex.
- Granulocyte Colony-Stimulating Factor-Primed Unmanipulated Haploidentical Blood and Marrow Transplantation.Frontiers in immunology · 2019Review
- [Advances in haploidentical hematopoietic stem cell transplantation for myelodysplastic syndromes].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2017Article
- [Strategy to improve clinical outcome of unmanipulated haploidentical stem cell transplantation without in vitro T cell depletion].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2016Article
- [Haploidentical transplantation for the treatment of intermediate- or high- risk acute myeloid leukemia in first complete remission: guideline and practice].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2016Article
- Recent advances in haploidentical hematopoietic stem cell transplantation using ex vivo T cell-depleted graft in children and adolescents.Blood research · 2016Review
- Haploidentical Bone Marrow Transplantation in 2015 and Beyond.Current oncology reports · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Unmanipulated haploidentical blood and marrow transplantation (HBMT) has been one of the most applied haploidentical transplant protocol, which offers rapid immune recovery, desirable health-related quality of life and comparable survival rate with those who received HLA-identical sibling transplantation or HLA-matched unrelated donor transplantation. Compared with HLA-identical sibling recipients, HBMT recipients experienced a lower risk of late effects. The HBMT protocol also shows superior in treating pediatric hematological malignancies compared with umbilical cord blood transplantation and could be successfully used as a post-remission treatment algorithm for adults acute myeloid leukemia with unfavorable cytogenetics. Several approaches, including optimal dose investigation of anti-thymocyte globulin, selecting the best donor, and modified donor lymphocyte infusion, have been designed to improve transplant outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.